Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye

Hagigit T., Abdulrazik M., Orucov F., Valamanesh F., Lambert M., Lambert G., Behar-Cohen F., Benita S.

2010
Journal of Controlled Release

View publication

Therapeutic Area

Back of the eye (BOTE)
Categories

Preclinical development

Affiliations

Department of Pharmaceutics, The School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel; Department of Ophthalmology, Hadassah, Hebrew University Medical Center, Jerusalem, Israel; INSERM U598, Paris, France; Novagali, Evry, France; Rothschild Foundation, Paris, France

Related Publications

STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24‑Month Results of a Randomized, Double‑Masked, Vehicle‑Controlled Trial of Atropine Sulfate 0.01% and 0.03%

Korenfeld M.; Hurcikova M.; Tatsuoka K.; Cheetham J.; Kacerik M.; on behalf of the STAR Study Investigators

Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.

Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review

de Milliano T. WL, Shi-van Wielink K., Ernst F., Mulkalapalli N., Pagidigummula R., Lymperopoulou C.

View all Back of the eye (BOTE) publications